Literature DB >> 28184434

Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.

Taha Ahmad1, Samie Sabet1, Donald A Primerano1, Lauren L Richards-Waugh2, Gary O Rankin1.   

Abstract

Cytochrome P450 (CYP) enzyme 2B6 plays a significant role in the stereo-selective metabolism of (S)-methadone to 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine, an inactive methadone metabolite. Elevated (S)-methadone can cause cardiotoxicity by prolonging the QT interval of the heart's electrical cycle. Large inter-individual variability of methadone pharmacokinetics causes discordance in the relationship between dose, plasma concentrations and side effects. The purpose of this study was to determine if one or more single nucleotide polymorphisms (SNPs) located within the CYP2B6 gene contributes to a poor metabolizer phenotype for methadone in these fatal cases. The genetic analysis was conducted on 125 Caucasian methadone-only fatalities obtained from the West Virginia and Kentucky Offices of the Chief Medical Examiner. The frequency of eight exonic and intronic SNPs (rs2279344, rs3211371, rs3745274, rs4803419, rs8192709, rs8192719, rs12721655 and rs35979566) was determined. The frequencies of SNPs rs3745274 (*9, c516G > T, Q172H), and rs8192719 (21563 C > T) were enhanced in the methadone-only group. Higher blood methadone concentrations were observed in individuals who were genotyped homozygous for SNP rs3211371 (*5, c1459C > T, R487C). These results indicate that these three CYP2B6 SNPs are associated with methadone fatalities.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28184434      PMCID: PMC5412025          DOI: 10.1093/jat/bkw135

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  44 in total

1.  Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles.

Authors:  Thomas Lang; Kathrin Klein; Tanja Richter; Arne Zibat; Reinhold Kerb; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  J Pharmacol Exp Ther       Date:  2004-06-09       Impact factor: 4.030

2.  Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo.

Authors:  Thien-An Nguyen; Marina Tychopoulos; Florence Bichat; Clothilde Zimmermann; Jean-Pierre Flinois; Monique Diry; Emelie Ahlberg; Marcel Delaforge; Laurent Corcos; Philippe Beaune; Patrick Dansette; François André; Isabelle de Waziers
Journal:  Mol Pharmacol       Date:  2008-01-22       Impact factor: 4.436

Review 3.  Pharmacogenomics of methadone maintenance treatment.

Authors:  Andrew A Somogyi; Daniel T Barratt; Robert L Ali; Janet K Coller
Journal:  Pharmacogenomics       Date:  2014-05       Impact factor: 2.533

Review 4.  Methadone: a review of drug-drug and pathophysiological interactions.

Authors:  Bhushan M Kapur; Janine R Hutson; Tamanna Chibber; Adriana Luk; Peter Selby
Journal:  Crit Rev Clin Lab Sci       Date:  2011 Jul-Aug       Impact factor: 6.250

5.  Free and bound enantiomers of methadone and its metabolite, EDDP in methadone maintenance treatment: relationship to dosage?

Authors:  D C Lehotay; S George; M L Etter; K Graybiel; J C Eichhorst; B Fern; W Wildenboer; P Selby; B Kapur
Journal:  Clin Biochem       Date:  2005-11-10       Impact factor: 3.281

Review 6.  Methadone--metabolism, pharmacokinetics and interactions.

Authors:  Anna Ferrari; Ciro Pio Rosario Coccia; Alfio Bertolini; Emilio Sternieri
Journal:  Pharmacol Res       Date:  2004-12       Impact factor: 7.658

7.  Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22).

Authors:  Takashi Watanabe; Kanako Sakuyama; Takamitsu Sasaki; Yuya Ishii; Masaaki Ishikawa; Noriyasu Hirasawa; Masahiro Hiratsuka
Journal:  Pharmacogenet Genomics       Date:  2010-07       Impact factor: 2.089

Review 8.  Searching for genetic determinants in the new millennium.

Authors:  N J Risch
Journal:  Nature       Date:  2000-06-15       Impact factor: 49.962

9.  Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.

Authors:  Maria Dobrinas; Séverine Crettol; Beatrice Oneda; Rachel Lahyani; Margalida Rotger; Eva Choong; Rubin Lubomirov; Chantal Csajka; Chin B Eap
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

10.  The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine.

Authors:  K Kristensen; C B Christensen; L L Christrup
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

View more
  12 in total

Review 1.  Pharmacogenetics of Opioid Use Disorder Treatment.

Authors:  Richard C Crist; Toni-Kim Clarke; Wade H Berrettini
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

2.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Pharmacogenetics of Methadone Response.

Authors:  Francina Fonseca; Marta Torrens
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

Review 4.  Pharmacogenomics of methadone: a narrative review of the literature.

Authors:  Senthil Packiasabapathy; Blessed W Aruldhas; Nicole Horn; Brian R Overholser; Sara K Quinney; Janelle S Renschler; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2020-07-24       Impact factor: 2.533

5.  Pharmacogenetics of Addiction Therapy.

Authors:  David P Graham; Mark J Harding; David A Nielsen
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.

Authors:  Taha Ahmad; Monica A Valentovic; Gary O Rankin
Journal:  Biochem Pharmacol       Date:  2018-02-16       Impact factor: 5.858

7.  Identification of a sex-stratified genetic algorithm for opioid addiction risk.

Authors:  David Bright; Anna Langerveld; Susan DeVuyst-Miller; Claire Saadeh; Ashley Choker; Elisabeth Lehigh; Stephanie Wheeler; Ahed Zayzafoon; Minji Sohn
Journal:  Pharmacogenomics J       Date:  2021-02-15       Impact factor: 3.550

8.  Investigating the CYP2B6 rs3745274 and rs3211371 polymorphisms in Methadone-Responder and Non-Responder Addicts in Iran.

Authors:  Sara Sadat Aghabozorg Afjeh; Behzad Boshehri; Safar Hamednia; Asmaolhosna Amini; Parisa Mashayekhi; Mir Davood Omrani
Journal:  Iran Biomed J       Date:  2021-02-06

9.  Novel associations between CYP2B6 polymorphisms, perioperative methadone metabolism and clinical outcomes in children.

Authors:  Senthil Packiasabapathy; Blessed W Aruldhas; Pengyue Zhang; Brian R Overholser; Sara K Quinney; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2021-06-08       Impact factor: 2.533

10.  ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms do not affect methadone maintenance treatment in HCV-positive patients.

Authors:  Davorka Sutlović; Željko Ključević; Sendi Kuret
Journal:  Arh Hig Rada Toksikol       Date:  2020-12-31       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.